Covilife 24 mg

When prescribed for a confirmed infection caused by susceptible parasites, Covilife 24 mg can:

• Reduce susceptible parasite activity

• Help clear intestinal strongyloidiasis

• Control microfilariae in onchocerciasis

• Reduce scabies mite activity

• Improve parasite-related itching

• Support recovery from diagnosed parasitic infections

These benefits depend on an accurate diagnosis and correctly calculated dosage. Ivermectin does not treat every worm, skin condition or cause of itching.

Ivermectin attaches to chloride channels in the nerve and muscle cells of susceptible parasites. This increases the flow of chloride ions and interrupts the signals required for movement and survival.

The affected parasites become paralysed and die or lose their ability to remain inside the body. The body then removes them naturally.

Cancer research is examining whether ivermectin also affects tumour-cell signalling and immune responses. These effects remain investigational and are separate from its established antiparasitic action.

Ivermectin dosage is calculated using body weight and the diagnosed infection. The 24 mg printed on the pack describes the amount in one tablet. It does not mean one complete tablet is suitable for every patient.

For strongyloidiasis, oral ivermectin is commonly prescribed at approximately 200 micrograms per kilogram of body weight as a single dose. For onchocerciasis, the commonly used calculated dose is approximately 150 micrograms per kilogram. Scabies requires a different schedule and often includes a repeat dose after a defined interval.

These figures are general ivermectin dosing references and should not be used to calculate a personal dose. Covilife 24 mg is a high-strength tablet, so the exact amount must be confirmed carefully.

Swallow the prescribed dose with water. Oral ivermectin is generally taken on an empty stomach. Do not repeat the dose because itching or other symptoms continue.

No established Covilife 24 mg dosage exists for COVID-19 or cancer, as the clinical trials are still ongoing. Online protocols and clinical-trial schedules should not be followed outside supervised research.

Common Side Effects: Covilife 24 mg can cause nausea, diarrhoea, abdominal discomfort, dizziness, headache, weakness, itching or a skin rash. Some reactions result from the body responding to dying parasites. Contact a healthcare professional if the symptoms continue or become difficult to manage.

Serious Side Effects: Seek urgent medical attention for facial swelling, breathing difficulty, fainting, severe skin reactions, confusion, seizures, difficulty walking, unusual drowsiness, vision changes or yellowing of the skin or eyes. People with a heavy Loa loa infection can develop a serious neurological reaction after taking ivermectin.

Covilife 24 mg should be avoided or used only after professional assessment by:

• People allergic to ivermectin

• Children weighing under 15 kg

• Pregnant or breastfeeding women

• People with severe liver disease

• People with suspected Loa loa infection

• People taking warfarin

• People using interacting medicines

• People seeking COVID-19 self-treatment

• People seeking cancer self-treatment

Tell the healthcare professional about all medicines, supplements and herbal products being used.

Important interactions include:

• Warfarin and other anticoagulants

• Azole antifungal medicines

• Macrolide antibiotics

• HIV protease inhibitors

• Anti-seizure medicines

• Sedating medicines

• Other antiparasitic medicines

• Chemotherapy or immunotherapy

Do not combine Covilife with another ivermectin product or an experimental treatment without professional review.

• Store the tablets in their original packaging.

• Keep them in a cool and dry place.

• Protect the pack from direct sunlight.

• Keep it away from excessive heat and moisture.

• Store it out of reach of children and pets.

• Do not use damaged or discoloured tablets.

• Check the expiry date before use.

• Dispose of expired tablets according to local requirements.